Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M50.1Revenue (TTM) $M0.2Net Margin (%)-32,700.0Altman Z-Score-10.7
Enterprise Value $M15.0EPS (TTM) $-0.9Operating Margin %-32,507.0Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.6Pre-tax Margin (%)-32,699.5Higher ROA y-yN
Price/Book2.110-y EBITDA Growth Rate %-7.8Quick Ratio3.1Cash flow > EarningsY
Price/Sales1735-y EBITDA Growth Rate %-3.0Current Ratio3.1Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-95.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-173.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M96.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CYTR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CYTRGeorge Soros 2014-06-30 Sold Out $2.92 - $5.31
($3.79)
$ 0.52-86%Sold Out0
CYTRGeorge Soros 2014-03-31 Buy $3.18 - $8.08
($5.96)
$ 0.52-91%New holding81,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CYTR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CYTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patterson Scott Bradford10% Owner 2013-12-03Buy284,979$2.44-78.69view
Patterson Scott Bradford10% Owner 2013-11-07Buy50,000$2.06-74.76view
Patterson Scott Bradford10% Owner 2013-04-01Buy4,083$2.7-80.74view
Patterson Scott Bradford10% Owner 2013-03-20Buy35,520$2.58-79.84view
Patterson Scott Bradford10% Owner 2013-03-20Buy3,980$2.61-80.08view
Patterson Scott Bradford10% Owner 2013-03-13Buy55,360$2.67-80.52view
Patterson Scott Bradford10% Owner 2012-10-22Buy180,000$2.51-79.28view
Patterson Scott Bradford10% Owner 2012-10-18Buy1,200,000$2.5-79.2view
Patterson Scott Bradford10% Owner 2012-06-28Buy44,824$5.14-89.88view
Patterson Scott Bradford10% Owner 2012-06-25Buy27,462$5-89.6view

Quarterly/Annual Reports about CYTR:

News about CYTR:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Dec 02 2016
Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors Dec 02 2016
CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA Nov 29 2016
CytRx Corp Conference Call to Discuss Results of Phase 3 Trial of Aldoxorubicin scheduled for 8:30... Nov 29 2016
CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin... Nov 29 2016
CYTRX CORP Files SEC form 8-K, Regulation FD Disclosure Nov 29 2016
CYTRX CORP Financials Nov 17 2016
CytRx Gets a Second Look (CYTR) Nov 16 2016
Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive Nov 15 2016
CYTRX CORP Files SEC form 8-K, Unregistered Sale of Equity Securities Nov 14 2016
CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical... Nov 11 2016
CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical... Nov 11 2016
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition Nov 09 2016
CytRx Reports Third Quarter 2016 Financial Results Nov 09 2016
CytRx reports 3Q loss Nov 09 2016
CytRx reports 3Q loss Nov 09 2016
CytRx Reports Third Quarter 2016 Financial Results Nov 09 2016
CYTRX CORP Files SEC form 10-Q, Quarterly Report Nov 09 2016
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Oct 19 2016
What CytRx Latest Trial Results Really Mean (CYTR) Oct 17 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)